Navigation Links
Swiss agency approves clinical trial of UCI-created neural stem cell therapy
Date:12/7/2010

A therapy developed by Aileen Anderson and Brian Cummings of UC Irvine's Sue and Bill Gross Stem Cell Research Center in collaboration with researchers at StemCells Inc. will be the basis of the world's first clinical trial using human neural stem cells to treat spinal cord injury.

Swissmedic, the Swiss regulatory agency for therapeutic products, has authorized a Phase I/II clinical trial for chronic spinal cord injury, cases in which inflammation has stabilized and recovery has reached a plateau.

The trial will utilize StemCells Inc.'s proprietary purified human neural stem cells and will be conducted at the University of Zurich's University Hospital Balgrist, one of the world's leading medical centers for spinal cord injury and rehabilitation.

It's designed to assess both safety and preliminary efficacy in patients with varying degrees of paralysis who are between three and 12 months post-injury at the time of transplantation. Enrollment is expected to begin in early 2011.

"This is tremendously exciting news," said Anderson, UCI associate professor of physical medicine & rehabilitation and anatomy & neurobiology. "Human neural stem cells may hold great promise for helping people with spinal cord injuries regain lost function."

In their collaboration with StemCells Inc., Anderson and Cummings conducted eight years of preclinical studies in rodents that demonstrated the significant therapeutic potential of human neural stem cells.

Their efforts have shown how these cells, when transplanted into damaged spinal columns, can differentiate into neural tissue cells such as oligodendrocytes and early neurons and migrate to injury sites. In recent studies, the researchers found that the treatment restored hind-limb function in mice when transplanted in the early chronic period after spinal cord injury.

Other stem cell studies have focused on the acute, or early, phase of spinal cord injury, a period of up to a few weeks after the initial trauma when drug therapies can lead to some functional recovery. The Swiss trial is significant because it will test treatment safety and restoration of mobility during the chronic, or later, phase. There are currently no drug therapies to help restore function during this phase.

"About 1.3 million individuals in the U.S. are living with chronic spinal cord injury," said Cummings, UCI associate professor of physical medicine & rehabilitation and anatomy & neurobiology. "This trial will be the first opportunity to demonstrate that human neural stem cells may be a viable treatment approach for them."


'/>"/>

Contact: Tom Vasich
tmvasich@uci.edu
949-824-6455
University of California - Irvine
Source:Eurekalert  

Related medicine news :

1. Jion Beijing Great Wall International Travel Agency Immediate Exposure to China Expo 2010
2. Home Health Agency Owner Pleads Guilty in Connection with Detroit Fraud Scheme
3. MARC Coalition Applauds Agencys Alert Regarding Delay in Data Exchange Deadline
4. Aid Agency World Vision Granted $19m From USAID/OFDA for Haiti
5. Nurse Staffing Agency, FlexRN, Unveils New Corporate Branding & Website
6. International Collaboration: FDA and European Medicines Agency Agree to Accept a Single Orphan Drug Designation Annual Report
7. USHEALTH Career Agency Announces Americas Choice
8. Lloyds of London News Features New Life Agency, Inc.
9. Savannah, Georgia, Insurance Agency Celebrates Over 30 Years of Service
10. The European Medicines Agency Completes Validation Stage for InterMunes Marketing Authorization Application for pirfenidone
11. Agency Pioneer SVH Tours & Travel Launches AppleSpecials.com, New Travel Booking Web Site that Showcases First-Hand Videos and Last Minute Specials
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Swiss agency approves clinical trial of UCI-created neural stem cell therapy
(Date:2/24/2017)... ... 2017 , ... Houston dentist , Dr. Behzad Nazari, ... Center. Currently, patients can get single dental implants for $3,599 and All On ... more about these offers by contacting Antoine Dental Center. Both of these options ...
(Date:2/24/2017)... ... February 24, 2017 , ... Dr. ... has officially announced the appointment of Peter A. Bell, DO, MBA, HPF, FACOEP-dist., ... (LUCOM), beginning April 10. Dr. Bell comes to Liberty from the Ohio ...
(Date:2/24/2017)... ... ... Healthcare Associates of McKinney announced today that they have moved one ... 121, Suite 210, McKinney, Texas 75070. It is in the heart of the ... has grown, the need for more space has been paramount. This beautiful new ...
(Date:2/24/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has published a ... an astounding statement when he says that the entire Bible was written for the ... times so plainly that anyone should be able to see the time period. He ...
(Date:2/24/2017)... ... February 24, 2017 , ... ... specializes in thought leadership , media relations, social media, content marketing and ... will be powered through Act-On, an intuitive marketing automation platform. , Rosica will ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... N.C. , Feb. 24, 2017 ... exploring ways to increase their self-service capabilities to ... Care Providers (HCPs). New research from ... pharma organizations have developed self-service website portals where ... This is just one of many findings to ...
(Date:2/24/2017)... 24 février 2017 ITL Limited, ( ASX : ITD ), ... ravie d,annoncer les excellents résultats semestriels clos le 31 ... Une présentation complète « Résultats et mise à jour sur ... . Faits marquants ... 1,04 million $ ; en hausse de 104 %) ...
(Date:2/24/2017)... Medivir AB (Nasdaq Stockholm: MVIR) ... Board of Directors that will be submitted to the ... representatives of the company,s three largest shareholders at the ... accepted a seat on the Nomination Committee, and the ... Nomination Committee was as follows:  ...
Breaking Medicine Technology: